Teva Pharmaceuticals Europe has received marketing authorization for Seffalair and BroPair Spiromax in the European Union to treat asthma. The drugs have been approved as maintenance treatment for asthma in patients above 12 years of age. Paul Blonk, Head of Teva (TEVA) Respiratory Europe, said, “We are excited about the European approval of Seffalair Spiromax and BroPair Spiromax, as an important goal of our respiratory franchise is to bring new treatment options to healthcare professionals who support people living with long-term conditions such as asthma.”  Blonk added, “We want to empower patients to effectively manage their condition through the medicines we provide, whilst also offering cost-effective treatments to healthcare systems.